All In Biotech

Drug Trial Radar · NCT07835074

A Study to Evaluate DEP114 for the Treatment of Acute Exacerbation of Persistent Allergic Rhinitis in Children Aged 6 to Under 12 Years

A Phase 3, Multicenter, Double-blind, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of DEP114 in the Treatment of Acute Exacerbation of Persistent Allergic Rhinitis in Children Aged 6 to Less Than 12 Years.

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 316 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

316

Planned (sponsor's estimate)

Start

Jun 2027

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Sep 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether DEP114 is effective in treating acute exacerbations of persistent allergic rhinitis in children aged 6 to less than 12 years. The study will also evaluate the safety of DEP114. Participants will: * Take DEP114 or desloratadine once daily for 5 days (up to a maximum of 7 days). * Keep a diary of their symptoms.

Conditions

  • Persistent Allergic Rhinitis

Interventions

  • DEP114Drug

    The participants must take 5 mL per day

  • DesloratadineDrug

    The participants must take 5 mL per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change in the Total Nasal Symptom Score (TNSS) for nasal congestion, rhinorrhea, nasal itching, and sneezing, measured 5 days after treatment initiation (TNSS₀-₅).Time frame: Day 5 after treatment initiation

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.